AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

Europe contemplates unified drug prices to counter US pressure to spend more. Experts are guarded in their expectations.

Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule.

Formulation differentiates therapies in crowded markets by improving adherence, tolerability, convenience, and delivery efficiency.